Merck & Co. Inc., one of the largest pharmaceutical companies in the world, announced yesterday that Health Canada has approved GARDASIL(R) (Human Papillomavirus Quadrivalent - Types 6, 11, 16, and 18 - Recombinant Vaccine) for boys and men nine through 26 years of age for the prevention of infection caused by HPV types 6, 11, 16, and 18 and genital warts caused by HPV types 6 and 11.
This approval follows the evidence related to consistently support the sexually transmitted nature of HPV and the role of men in infecting women, who subsequently can develop HPV-related ano-genital cancers and genital warts. Based on these various lines of evidence it is expected that decreasing the risk of HPV infection in men through vaccination should decrease the risk of infection in their sexual partners, thereby providing additional public health benefit.
No User Responded In This Post
Before Leave Your Comments Here Click Below On Our Sponsors...